Contents

The document from 2010 reviews various innovative dermatological treatments for conditions such as severe hand dermatitis, pruritus, recurrent furunculosis, lupus erythematosus, cutaneous T-cell lymphoma, and hidradenitis suppurativa, as well as the use of several medications like topical metronidazole, calcineurin inhibitors, rituximab, TNF-α inhibitors, thalidomide, zinc, dapsone, and spironolactone. It emphasizes the complexity of treating these conditions, such as the need to address underlying causes in hand dermatitis and the challenges in managing pruritus and recurrent furunculosis. The document also discusses new treatments for lupus erythematosus and cutaneous T-cell lymphoma, the efficacy of biologic drugs for hidradenitis suppurativa, and various off-label uses of medications in dermatology. Specifically, it notes the effectiveness of spironolactone in treating female pattern hair loss by arresting hair loss and inducing partial regrowth. Additionally, it mentions innovative pediatric dermatological therapies, including oral propranolol for infantile hemangiomas and proactive use of topical calcineurin inhibitors for atopic dermatitis.